Logo

PharmaShots Weekly Snapshots (October 21 – October 25, 2024)

Share this

PharmaShots Weekly Snapshots (October 21 – October 25, 2024)

This week PharmaShots’ news was all about the updates on Clinical Trials, Regulatory, Pharma, MedTech, M&A, Biosimilars & Biotech. Check out our full report below:

 

 

Merck and Gilead Highlight the P-II Study Data of Islatravir Plus Lenacapavir in Virologically Suppressed People with HIV at IDWeek 2024

Read More: Merck and Gilead

Roche Reports 1-Year Data from P-IV (ELEVATUM) Study of Vabysmo (Faricimab) in Patients with Diabetic Macular Edema (DME)

Read More: Roche

Alto Neuroscience’s P-IIb Trial of ALTO-100 for Major Depressive Disorder Couldn’t Achieve its Primary Endpoint

Read More: Alto Neuroscience

Hope Medicine Reports the Data from P-II Trial of HMI-115 for Treating Endometriosis

Read More: Hope Medicine

Alkeus Pharmaceuticals Reports Topline Results from SAGA Trial of Gildeuretinol (ALK-001) for Geographic Atrophy Secondary to Age-Related Macular Degeneration

Read More: Alkeus Pharmaceuticals

Zai Lab Highlights the Data from P-Ia/Ib Trial of ZL-1310 for Treating Extensive-Stage Small Cell Lung Cancer at ENA Symposium 2024

Read More: Zai Lab

Abbott Commences New Clinical Trial to Enhance Patient Outcomes in Advanced Heart Failure

Read More: Abbott

EyePoint Pharmaceuticals Reports the First Patient Dosing in P-III (LUGANO) Study of Duravyu to Treat Wet Age-Related Macular Degeneration

Read More: EyePoint Pharmaceuticals

 

AbbVie Reports the US FDA’s Approval of Botox Cosmetic (OnabotulinumtoxinA) for Moderate to Severe Vertical Bands Connecting the Jaw and Neck

Read More: AbbVie

AstraZeneca and Ionis’ Wainzua (Eplontersen) Receives the CHMP’s Positive Opinion to Treat Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy

Read More: AstraZeneca and Ionis

Astellas Reports the US FDA’s Approval of Vyloy (Zolbetuximab-clzb) to Treat Advanced G/GEJ Cancer

Read More: Astellas

BeiGene Reports the CHMP’s Positive Opinions for Tevimbra as a 1L Treatment of G/GEJ Cancer and Esophageal Squamous Cell Carcinoma

Read More: BeiGene

Adcentrx Therapeutics Reports the US FDA’s IND Clearance of ADRX-0405 to Treat Advanced Solid Tumors

Read More: Adcentrx Therapeutics

Eli Lilly Reports the MHRA’s Approval of Kisunla (Donanemab) to Treat Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease

Read More: Eli Lilly

HiberCell’s HC-7366 Gains the US FDA’s Fast Track Designation for Treating Acute Myeloid Leukemia (AML)

Read More: HiberCell

Merck Reports EC’s Approval of Keytruda for Two New Indications in Gynecologic Cancers

Read More: Merck

Accent Therapeutics Receives the US FDA’s IND Approval of ATX-559 for Treating Breast Cancer

Read More: Accent Therapeutics

 

Angelini Pharma Join Forces with Cureverse to Develop and Commercialize CV-01 for Brain Health

Read More: Angelini Pharma and Cureverse

Avacta Therapeutics Collaborates with Tempus AI to Commence AI-Driven Drug Development in Oncology

Read More: Avacta Therapeutics and Tempus AI

GSK Enters into a 5-Year Partnership with Cambridge University to Address Kidney and Respiratory Diseases

Read More: GSK

Telix Spins Off Rhine Pharma to Broaden Global Radiopharmaceutical Reach

Read More: Telix

Eccogene Reports the First Patient Dosing with ECC5004/AZD5004 in P-IIb Trial of Obesity and T2D, Triggering $60M Milestone from AstraZeneca

Read More: Eccogene and AstraZeneca

EydisBio Receives $0.5M Grant to Support the Development of TAK1 Inhibitor Program for Alzheimer's Disease

Read More: EydisBio

AbbVie Inks Pact with Gedeon Richter to Discover and Develop Novel Targets for Neuropsychiatric Conditions

Read More: AbbVie and Gedeon Richter

Dyno Therapeutics Collaborates with Roche to Develop AAV Gene Therapy Vectors for Neurological Diseases

Read More: Dyno Therapeutics and Roche

 

Teal Health Reports the Regulatory Submission of Teal Wand to the US FDA for Cervical Cancer Screening

Read More: Teal Health

 

Ocuphire Pharma to Acquire Opus Genetics

Read More: Ocuphire Pharma

 

Dong-A ST Receives the CHMP’s Positive Opinion for Imuldosa (Biosimilar, Stelara)

Read More: Dong-A ST

Alvotech and Teva Reports the US FDA’s Approval for the Additional Presentation of Selarsdi (Biosimilar, Stelara)

Read More: Alvotech and Teva

 

Poseida Therapeutics to Feature Non-Clinical Data of P-KLKB1-101 for Treating Hereditary Angioedema at ACAAI 2024

Read More: Poseida Therapeutics

 

Related Post: PharmaShots Weekly Snapshots (October 14 – October 18, 2024)


Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions